It’s all about franchise protection

This morning Lilly made the following announcement:

“Eli Lilly and Company (NYSE: LLY) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly's connected diabetes solutions. Under the terms of the agreement, Lilly will commercialize the system, which is currently in development and will include an insulin pump developed and manufactured by Ypsomed.”

Now keep in mind this will be the SECOND insulin pump Lilly has, the first not yet launched pump is a Dean Kamen design which Dean has sold more than once. (Nice . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.